LCB43: A Next-Generation Beta-Glucuronide BCMA ADC for the Treatment of Multiple Myeloma
10:45 am - Tuesday 9th March 2027
- Belantamab Mafodotin is a great ADC held back by ocular toxicity
- Sharing clinical evidence of less ocular toxicity
- Addressing the key limitation of blenrep using LCB43, a next-generation ADC
